Aptevo Therapeutics Inc. (APVO): Entry into a Material Definitive Agreement
Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 23, 2026, Aptevo Therapeutics Inc. (the “Company”) entered into Amendment No. 6 (the “Amendment”) to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions,
How this was made
The 30-second read
Why it matters
The amendment adjusts the purchase price and extends the expiration, which may affect the dilution profile and pricing of the preferred securities.
Market read
A material corporate action for a micro‑cap biotech, likely to cause modest short‑term price movement.
What to watch
Potential downstream effects on future financing rounds or conversion of the preferred shares.
Background
Aptevo Therapeutics (APVO) is a clinical‑stage biotech focused on oncology and immunology. The Rights Agreement governs the purchase of fractional preferred shares by rights‑holders.
Ticker impact
Aptevo Therapeutics filed an 8‑K reporting Amendment No. 6 to its Rights Agreement, changing the purchase price to $14.56 per preferred share and extending the expiration date to Oct 23 2027.
potential modest pressure as the market prices in the higher purchase price for the rights offering
Rights agreement amendments are corporate actions that can adjust the economics of existing convertible securities, leading to short‑term price adjustments.
Market effects
Limited impact; primarily relevant to biotech micro‑cap investors and rights‑holders.
US biotech micro‑cap segment.
Low; no broader market effect.
Counterpoint
The amendment could be seen as a positive, signaling stronger capital support and potentially higher future equity value.
Key entities
- companyAptevo Therapeutics Inc.
Issuer of the Rights Agreement amendment.
- service_providerBroadridge Corporate Issuer Solutions, LLC
Rights agent for the agreement.